Evidence map›Paper›PMID 34481846›Full record

ArticleGastroenterology2022

Single-Cell DNA Sequencing Reveals Punctuated and Gradual Clonal Evolution in Hepatocellular Carcinoma.

Lin Guo, Xianfu Yi, Lu Chen, Ti Zhang, Hua Guo, Ziye Chen, Jinghui Cheng, Qi Cao, Hengkang Liu, Chunyu Hou and 10 more

Abstract read
PubMed Publisher
In one paragraph

Article in Gastroenterology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
4.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 84 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 3 institutions in 1 country.

Lin GuoLaboratory of Tumor Cell Biology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China; Department of Genetics, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China.
Xianfu YiSchool of Biomedical Engineering and Technology, Department of Bioinformatics, The Province and Ministry Co-Sponsored Collaborative Innovation Center for Medical Epigenetics, Tianjin Medical University, Tianjin, China.
Lu ChenLaboratory of Tumor Cell Biology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China; Department of Hepatobiliary Cancer, Liver Cancer Research Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Ti ZhangDepartment of Hepatobiliary Cancer, Liver Cancer Research Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Hua GuoLaboratory of Tumor Cell Biology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Ziye ChenLaboratory of Tumor Cell Biology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Jinghui ChengTranslational Cancer Research Center, Peking University First Hospital, Beijing, China.
Qi CaoTranslational Cancer Research Center, Peking University First Hospital, Beijing, China.
Hengkang LiuTranslational Cancer Research Center, Peking University First Hospital, Beijing, China.
Chunyu HouTranslational Cancer Research Center, Peking University First Hospital, Beijing, China.
Lisha QiDepartment of Pathology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Zhiyan ZhuTianjin Research Center of Basic Medical Science, Tianjin Medical University, Tianjin, China.
Yucun LiuDivision of General Surgery, Peking University First Hospital, Beijing, China.
Ruirui KongTranslational Cancer Research Center, Peking University First Hospital, Beijing, China.
Chong ZhangBeijing International Center for Mathematical Research, Peking University, Beijing, China.
Xiaohua ZhouBIOPIC, Beijing Advanced Innovation Center for Genomics, and School of Life Sciences, Peking University, Beijing, China.
Zemin ZhangBeijing International Center for Mathematical Research, Peking University, Beijing, China.
Tianqiang SongDepartment of Hepatobiliary Cancer, Liver Cancer Research Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Ruidong XueTranslational Cancer Research Center, Peking University First Hospital, Beijing, China. Electronic address: rxue@hsc.pku.edu.cn.
Ning ZhangLaboratory of Tumor Cell Biology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China; Translational Cancer Research Center, Peking University First Hospital, Beijing, China. Electronic address: zhangning@bjmu.edu.cn.
Peking University · CNTianjin Medical University Cancer Institute and Hospital · CNTianjin Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND &

aimsCopy number alterations (CNAs), elicited by genome instability, are a major source of intratumor heterogeneity. How CNAs evolve in hepatocellular carcinoma (HCC) remains unknown.

methodsWe performed single-cell DNA sequencing (scDNA-seq) on 1275 cells isolated from 10 patients with HCC, ploidy-resolved scDNA-seq on 356 cells from 1 additional patient, and single-cell RNA sequencing on 27,344 cells from 3 additional patients. Three statistical fitting models were compared to investigate the CNA accumulation pattern.

resultsCells in the tumor were categorized into the following 3 subpopulations: euploid, pseudoeuploid, and aneuploid. Our scDNA-seq analysis revealed that CNA accumulation followed a dual-phase copy number evolution model, that is, a punctuated phase followed by a gradual phase. Patients who exhibited prolonged gradual phase showed higher intratumor heterogeneity and worse disease-free survival. Integrating bulk RNA sequencing of 17 patients with HCC, published datasets of 1196 liver tumors, and immunohistochemical staining of 202 HCC tumors, we found that high expression of CAD, a gene involved in pyrimidine synthesis, was correlated with rapid tumorigenesis and reduced survival. The dual-phase copy number evolution model was validated by our single-cell RNA sequencing data and published scDNA-seq datasets of other cancer types. Furthermore, ploidy-resolved scDNA-seq revealed the common clonal origin of diploid- and polyploid-aneuploid cells, suggesting that polyploid tumor cells were generated by whole genome doubling of diploid tumor cells.

conclusionsOur work revealed a novel dual-phase copy number evolution model, showed HCC with longer gradual phase was more severe, identified CAD as a promising biomarker for early recurrence of HCC, and supported the diploid origin of polyploid HCC.

Indexed as

Clonal EvolutionGenetic HeterogeneitySequence Analysis, DNASingle-Cell AnalysisAdultAgedBiomarkers, TumorCarcinoma, HepatocellularDisease-Free SurvivalDisease ProgressionDNA Copy Number VariationsFemaleGene DosageGene Expression Regulation, NeoplasticGenomic InstabilityHumansBiomarkers, TumorClonal EvolutionEarly RecurrenceLiver CancerPloidy Heterogeneity

Identifiers

PMID34481846
OpenAlexW3198396939

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.